Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Tofacitinib |
| Trade Name | Xeljanz |
| Synonyms | Tasocitinib|CP-690550|CP-690,550 |
| Drug Descriptions |
Xeljanz (tofacitinib) is a pan-JAK inhibitor, which decreases downstream signaling and potentially leads to reduced tumor cell growth (PMID: 26300391, PMID: 21106989). Xeljanz (tofacitinib) is FDA approved for rheumatoid arthritis (FDA.gov). |
| DrugClasses | JAK Inhibitor (Pan) - ATP competitive 3 |
| CAS Registry Number | 477600-75-2 |
| NCIT ID | C95800 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Dexamethasone + Tofacitinib | Dexamethasone Tofacitinib | 1 | 0 |
| LMB-100 + Tofacitinib | LMB-100 Tofacitinib | 0 | 1 |
| Midostaurin + Tofacitinib | Midostaurin Tofacitinib | 2 | 0 |
| Tofacitinib | Tofacitinib | 21 | 2 |